在肿瘤坏死因子抑制剂应答不足患者中鉴定沙利鲁单抗的药效学与预测标志物:3期TARGET研究的生物标志物子研究
该研究为3期TARGET研究的生物标志物子研究,评估沙利鲁单抗200mg或150mg每2周联合csDMARDs治疗中重度RA且TNF抑制剂应答不足或不耐受患者。结果显示沙利鲁单抗显著降低C1M、C3M、CXCL13、MMP-3和总RANKL水平,基线sICAM-1水平可预测200mg组第12周LDA应答。
要点
- 沙利鲁单抗联合csDMARDs显著降低滑膜炎症和骨吸收相关循环生物标志物。
- 基线sICAM-1水平可预测沙利鲁单抗200mg每2周组第12周LDA应答。
- 基线sICAM-1较低患者较sICAM-1较高患者应答更好,呈趋势性观察。
核心结论
- 沙利鲁单抗联合csDMARDs降低滑膜炎症和骨吸收的循环生物标志物,sICAM-1可预测沙利鲁单抗治疗达到LDA。
研究设计与样本
- 3期TARGET研究(NCT01709578)的生物标志物子研究,纳入中重度RA且对TNF抑制剂应答不足或不耐受的成人患者。
- 患者接受皮下沙利鲁单抗200mg或150mg每2周联合csDMARDs,或安慰剂联合csDMARDs。
主要发现
- 沙利鲁单抗较安慰剂在第24周显著降低C1M、C3M、CXCL13、MMP-3和总RANKL水平。
- 部分标志物在第2周即显著抑制,并恢复正常对照水平。
- 基线sICAM-1较低患者较sICAM-1较高患者应答更好,呈趋势性观察。
关键数值与推荐
- 沙利鲁单抗200mg或150mg每2周皮下给药联合csDMARDs。
- 第24周C1M、C3M、CXCL13、MMP-3和总RANKL较安慰剂显著降低。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Interleukin-6 (IL-6) orchestrates formation of an inflammatory pannus, leading to joint damage in rheumatoid arthritis (RA). Sarilumab is a human monoclonal antibody blocking the IL-6Rα. In TARGET (NCT01709578), a phase 3 study in adults with moderate-to-severe RA and inadequate response or intolerance to tumour necrosis factor inhibitors, subcutaneous sarilumab 200 mg or 150 mg every 2 weeks (q2w) plus conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) significantly reduced disease activity versus placebo plus csDMARDs. METHODS: Circulating levels of biomarkers associated with synovial inflammation (matrix metalloproteinase 3 (MMP-3), collagen type I MMP-cleaved fragment (C1M), collagen type III MMP-cleaved fragment (C3M)), myeloid (soluble intercellular adhesion molecule 1 (sICAM-1), IL-8 and calprotectin) and lymphoid activation (chemokine, CXC motif, ligand 13 (CXCL13), CXCL10, B cell-activating factor) and bone remodelling (receptor activator of nuclear factor-κB ligand (RANKL), osteoprotegerin and osteocalcin) were evaluated in patients from a TARGET substudy. RESULTS: Sarilumab significantly decreased C1M, C3M, CXCL13, MMP-3 and total RANKL levels at week 24 versus placebo; some markers were significantly suppressed at week 2 and normalised to levels in healthy controls. Levels of sICAM-1 were predictive of disease activity score by C-reactive protein and clinical disease activity index low disease activity (LDA) response in the sarilumab 200 mg q2w group at week 12. A trend was observed in which patients with lower sICAM-1 levels at baseline had better response compared with patients with higher sICAM-1. CONCLUSIONS: Sarilumab plus csDMARDs decreased circulating biomarkers of synovial inflammation and bone resorption; sICAM-1 was predictive of achieving LDA with sarilumab. TRIAL REGISTRATION NUMBER: NCT01709578; Post-results.
引用
- Gabay C, Msihid J, Zilberstein M, et al. Identification of sarilumab pharmacodynamic and predictive markers in patients with inadequate response to TNF inhibition: a biomarker substudy of the phase 3 TARGET study. RMD Open. 2018. PMID: 29556418. doi:10.1136/rmdopen-2017-000607
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。